Contribute Try STAT+ Today

The Covid-19 pandemic is taking a harsh toll on small biotech companies, many of which have only enough cash for the next year of operations and expect they will have to reduce the amount of money sought in new financing rounds or delay such efforts altogether, a new survey finds.

Not surprisingly, a growing number of these companies are coping by reducing staff, slashing compensation, or cutting spending on pre-clinical trial programs, according to the survey of 106 biotech companies by the Bernstein investment bank and BioCentury.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.